Relay Therapeutics (RLAY) Jefferies London Healthcare Conference 2024 summary

Key data and clinical development updates

• Presented promising data for RLY-2608 in HR-positive, HER2-negative metastatic breast cancer, showing a 33% response rate and 9.2 months median PFS in PI3K alpha mutated patients.

• Phase III pivotal trial for RLY-2608 is being prepared, aiming for rapid patient access.

• Combination strategies focus on pairing RLY-2608 with best-in-class agents like fulvestrant, ribociclib, and atirmociclib, with triplet regimens under evaluation.

• Favorable safety profile observed, with manageable cytopenias and no anticipated synergistic toxicity in combinations.

• Additional programs include an NRAS selective molecule and a Fabry disease initiative, supported by $850 million in recent financing.

Competitive landscape and differentiation

• RLY-2608 demonstrates higher response rates and PFS compared to standard of care and competitors, with 53% response and 10.3 months PFS in kinase domain subgroup.

• Competitor molecules face challenges such as higher toxicity or discontinuation, reinforcing confidence in RLY-2608's position.

• Emphasis on maximizing dose intensity and selectivity to improve efficacy and tolerability in broader patient populations.

• Ongoing efforts to maintain commercial lead and respond to evolving standards of care.

Future plans and strategic focus

• Phase III trial launch planned for next year, with continued data maturation and updates expected as studies progress.

• Exploring additional combinations, including with oral SERDs and CDK2 inhibitors, to address resistance mechanisms and expand indications.

• PI3K alpha remains the backbone for targeted therapy in mutated patients, with ongoing preclinical and clinical synergy studies.

• Focus on clinical benefit rate and progression-free survival as key endpoints for regulatory and commercial success.